ANI Pharmaceuticals
ANIP
68.55
-0.58
-0.84%
ANI Pharmaceuticals
US · ANIP
#2919 by market cap
Listed 1970
68.55
-0.58
-0.84%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership rose 4.7 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 122.29% +4.68pp
- Institutions
- 362 -4
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund84.43%
Hedge Fund16.83%
Public Company9.06%
Individual/Insider6.21%
VC/PE Fund4.79%
Private Company3.91%
Government Pension Fund2.90%
Insurance Company0.25%
Top holders as of 2026-09-30
BlackRock
14.90% · 3.16M sh
MVP Capital Partners
4.79% · 1.01M sh
State Street Global Advisors
4.49% · 950.97K sh
American Century Investment Management
4.31% · 912.65K sh
Vanguard Capital Management, LLC
4.27% · 904.71K sh
Soleus Capital Management, L.P.
4.10% · 867.76K sh
Dimensional Fund Advisors
3.44% · 728.75K sh
Tang Capital Management, LLC
3.34% · 707.50K sh
UBS Asset Management
3.13% · 663.61K sh
Global Alpha Capital Management Ltd.
2.60% · 558.00K sh
Arrowstreet Capital, Limited Partnership
2.65% · 562.02K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 6 buys · 44 sells
| Name | Role | Stake |
|---|---|---|
| Nikhil Lalwani | Chief Executive Officer | 1.58% |
| Chad Gassert | Senior Vice President of Corporate Development & Strategy | 1.10% |
| Stephen Carey | Chief Financial Officer | 0.78% |
| Muthusamy Shanmugam | Head of R&D and COO of New Jersey Operations | 0.39% |
| Ori Gutwerg | Senior Vice President of Generics | 0.36% |
| Meredith Cook | Senior Vice President | 0.35% |
| Christopher Mutz | Senior Vp & Head of Rare Disease | 0.29% |
| Krista Davis | Chief Human Resources Officer | 0.25% |
| Thomas Haughey | Independent Chairperson | 0.18% |
| Patrick Walsh | Former Independent Chairperson | 0.18% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-12 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $70.80 |
| 2026-10-28 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $72.87 |
| 2026-10-14 | Nikhil Lalwani | Chief Executive Officer | Automatic Disposition | -5,400 | $71.89 |
| 2026-10-14 | Nikhil Lalwani | Chief Executive Officer | Intent to Sell (Form 144) | -5,400 | $70.16 |
| 2026-10-12 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $73.59 |
| 2026-09-28 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $73.00 |
| 2026-09-14 | Nikhil Lalwani | Chief Executive Officer | Automatic Disposition | -5,400 | $71.00 |
| 2026-09-13 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $70.79 |
| 2026-09-10 | Jeanne Thoma | Independent Director | Automatic Disposition | -1,000 | $71.53 |
| 2026-08-30 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $72.80 |
| 2026-08-24 | Nikhil Lalwani | Chief Executive Officer | Automatic Disposition | -5,400 | $74.30 |
| 2026-08-18 | Henry Gosebruch | Director | Other Acquisition | +6,662 | -- |
| 2026-08-12 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $75.48 |
| 2026-08-09 | Ori Gutwerg | Senior Vice President of Generics | Open Market Disposition | -3,162 | $77.00 |
| 2026-07-28 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $81.36 |
| 2026-07-17 | Meredith Cook | Senior Vice President | Sale to Issuer | -2,466 | $79.20 |
| 2026-07-12 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $81.84 |
| 2026-07-06 | Patrick Walsh | Former Independent Chairperson | Intent to Sell (Form 144) | -4,336 | $86.19 |
| 2026-07-01 | Stephen Carey | Chief Financial Officer | Derivative Exercise and Sale | -3,313 | $49.51–86.00 |
| 2026-06-28 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $84.12 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:05 · For reference only, not investment advice and not tailored to your situation.
ANI Pharmaceuticals discussion 0 comments